Our Mission

At Synvir, we want to change the game for drug development and help cure the world's most intractable diseases. 

The way next generation drugs are being developed requires a fundamentally different approach to producing both experimental drugs in laboratories and patient dosing in clinical environments. 

Unlike traditional pharmaceutical R&D processes, next generation drugs require a massive number of researchers working in specific, complementary areas to refine and test their individual components.

There are all kinds of specialists in different places working on individual components of a drug, as well as the people putting those pieces together to treat specific illnesses. Each of them requires the means to create and test what they're working on. That means small footprint, high-performance, cost-effective devices that are accessible to many, many laboratories and research institutions to support the drug discovery and development process.

As sequencing continues to move toward point-of-care , it is becoming an integral part of patient diagnosis. This will drive even greater demand for highly targeted  next generation drugs. 

In the clinical environment, next generation drugs will also require a mass personalization approach to individual dosing of patients. Producing patient-specific dosages will most likely occur on site or nearby rather than in large-scale, centralized manufacturing facilities.

Synvir has developed microfluidic particle production technology and devices designed to meet the needs of both drug development and patient dosing.